BridgeBio Pharma, Inc.
- Stock
- Ticker BBIO
- ISIN US10806X1028
- Nasdaq
Performance, volatility and drawdowns of BridgeBio Pharma, Inc. since 06/2019, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $15,397. Global equities (VT): $14,653.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −92.8% in 05/2022, measured from the peak in 02/2021. It took 58 months to get back to the old peak.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 5.9 | 117 | 111 | 121 | 154 | 195 | 244 | 353 |
| Gross profit | 3.8 | 114 | 107 | 114 | 146 | 185 | 229 | 333 |
| Operating income | -226 | -104 | -134 | -145 | -140 | -106 | -107 | -12 |
| EBITDA | -225 | -103 | -133 | -144 | -138 | -105 | -106 | -11 |
| Net income | -267 | -170 | -184 | -183 | -201 | -167 | -156 | -57 |
| Earnings per share | -1.42 | -0.88 | -0.95 | -0.95 | -0.99 | -0.84 | -0.78 | -0.42 |
| Balance sheet | ||||||||
| Total assets | 919 | 882 | 1,080 | 998 | 936 | 1,371 | 1,217 | 2,162 |
| Liabilities | 2,377 | 2,520 | 2,859 | 2,921 | 3,013 | 3,640 | 3,723 | 3,815 |
| Equity | -1,468 | -1,648 | -1,788 | -1,933 | -2,087 | -2,278 | -2,515 | -1,662 |
| Cash | 681 | 541 | 749 | 643 | 570 | 880 | 678 | 1,533 |
| Long-term debt | 437 | 0.0 | 0.0 | 2,007 | 2,007 | 2,653 | 2,653 | 2,630 |
| Cash flow | ||||||||
| Operating cash flow | -195 | -199 | -81 | -110 | -56 | -197 | -71 | -44 |
| Capital expenditure | 0.0 | 0.0 | -0.6 | -0.5 | 0.0 | -0.1 | -0.4 | -0.3 |
| Free cash flow | -195 | -199 | -81 | -110 | -56 | -197 | -72 | -44 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2023 at +429.8%, weakest 2021 at −76.5%. 3 of 6 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 29 Oct 2026 | −$0.42 |
| 10 Aug 2026 | −$0.78 |
| 7 May 2026 | −$0.84 |
| 24 Feb 2026 | −$0.99 |
| 29 Oct 2025 | −$0.95 |
| 5 Aug 2025 | −$0.95 |
| 29 Apr 2025 | −$0.88 |
| 20 Feb 2025 | −$1.42 |
| 12 Nov 2024 | −$0.86 |
| 1 Aug 2024 | −$0.39 |
| 2 May 2024 | −$0.20 |
| 22 Feb 2024 | −$0.96 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €13bn
- Market cap in trading currency
- $14.8bn
- Enterprise value
- $15.9bn
- P/E
- –
- P/S
- 15.66
- P/B
- –
- EV/Sales
- 16.82
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -2.5%
Results (last four quarters)
- Revenue
- $946m
- Gross profit
- $892m
- EBITDA
- −$359m
- Net income
- −$580m
- Earnings per share
- −$3.03
- Revenue per share
- $4.85
- Revenue growth
- +192.6%
- Earnings growth
- –
Profitability
- Gross margin
- 94.3%
- Operating margin
- -38.5%
- Net margin
- -61.3%
- Return on equity
- –
- Return on assets
- -26.8%
Balance sheet and cash flow
- Cash
- $1.54bn
- Cash per share
- $7.90
- Financial debt
- $2.63bn
- Debt/equity %
- –
- Current ratio
- 2.09
- Book value per share
- −$8.53
- Operating cash flow
- −$369m
- Free cash flow
- −$370m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 195m
- Volume
- 1.48m
- Avg. volume 3 months
- 2.68m
- Relative volume
- 0.6
Price and technicals
- Price
- $76.03
- 1 day
- −2.8%
- 52-week high
- $90.17
- 52-week low
- $63.30
- Distance to 52-week high
- −15.7%
- Distance to 52-week low
- +20.1%
- Distance to 50-day line
- +8.2%
- Distance to 200-day line
- +4.5%
- RSI (14)
- 55
- Volatility 1M
- 39.9%
Performance
- 1 week
- −2.9%
- 1 month
- +11.6%
- 3 months
- −6.2%
- 6 months
- +10.0%
- YTD
- −0.6%
- 1 year
- +16.0%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has BBIO performed since 06/2019?
$10,000 grew to $27,597 by 20 Nov 2026, which is +14.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is BBIO?
Volatility was 71.7% per year, measured on monthly returns. The largest decline from a peak was −92.8%, with the low in 05/2022.
How does BBIO compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.2% per year at 16.1% volatility, BBIO returned +14.7% at 71.7%. The correlation of monthly returns was 0.22; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.